A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).
Carole MercierPiet DirixPaul MeijndersPeter VermeulenSteven Van LaereHilde DeboisPhilippe HugetDirk VerellenPublished in: Radiation oncology (London, England) (2018)
The Ethics committee of the GZA Hospitals (B099201732915) approved this study on 05/07/2017. Amendment for translational research was approved on 06/02/2018. Trial registered on Clinicaltrials.gov ( NCT03486431 ) on 03/04/2018 - Retrospectively registered.
Keyphrases
- phase iii
- lymph node
- study protocol
- phase ii
- clinical trial
- open label
- early stage
- public health
- radiation therapy
- randomized controlled trial
- squamous cell carcinoma
- small cell lung cancer
- machine learning
- big data
- radiation induced
- locally advanced
- risk assessment
- rectal cancer
- postmenopausal women
- anaerobic digestion